Navigation Links
Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
Date:10/22/2013

events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Research and development risks, including risks associated with our work in the area of ARDS, our reliance on third-parties to conduct research and development, and the ability of research and development to generate successful results;
  • Our reliance on Acthar for substantially all of our net sales and profits and the possible FDA approval and market introduction of competitive products;
  • The lack of patent protection for Acthar;
  • Our ability to effectively manage our growth, including the expansion of our sales forces, planned international expansion, recent acquisitions, and our reliance on key personnel;
  • The risk of product liability lawsuits;
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission, or SEC, on February 27, 2013, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
2. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
3. Questcor to Commence Phase 2 Study of Acthar for ALS
4. Questcor to Report Second Quarter Financial Results on July 30, 2013
5. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. Questcor Adds Angus C. Russell to Board of Directors
8. Questcor Reports First Quarter Financial Results
9. Questcor to Report First Quarter Results on April 30, 2013
10. Questcor Reports Fourth Quarter and Full Year 2012 Results
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. ... equity financing. Led by Sears Capital Management and Biobrit ... Joe Zakrzewski , the $1.5 million financing positions SiteOne ... for pain and to further develop its technology platform ... indications. In conjunction with the financing, ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Pervasis Therapeutics, Inc. today announced that it has ... government,s Qualifying Therapeutic Discovery Project, which provides tax credits ... produce new therapies, reduce long-term health care costs, or ... next 30 years.   Pervasis is a ...
... 4, 2010 The physicians of Westside Medical Associates ... Beverly Hills , California have announced the results of a ... CT scans save lives.  According to Drs. Norman ... Medical Imaging, this study should once and for all settle ...
Cached Medicine Technology:Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 2Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 3Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 4Annual CT Lung Screening Saves Lives 2
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... PITTSBURGH, PA (PRWEB) September 23, 2014 "The ... and infection control," said an inventor from Sacramento, Ca.. "Call ... patient bedding or left hanging on the IV pole out ... patients have the nurse call device whenever they need it, ... CADDY to effectively position the nurse call device within easy ...
(Date:9/23/2014)... CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN ... , The National Institutes of Health is convening a ... evidence on the long-term effectiveness and potential risks of ... the nation,s top experts in the field of pain ... as key NIH scientists who focus on pain related ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer ... The presentation will be webcast live and can be accessed from ... , , About Endo , ...
... , , BERWYN, Pa., Aug. 31 ... service multinational clinical research organization (CRO) conducting studies in over 30 ... today announced that on August 25, 2009, it received a letter ... its Form 10-Q for the period ended June 30, 2009, NASDAQ ...
... , , SCOTTSDALE, ... today announced that, at the Company,s 2009 Annual Meeting of Stockholders, ... an overwhelming majority all of the Company,s nominees to the board ... 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding as of ...
... study, blood-thinning drug best for those at highest risk of ... patients, or those with a prior history of stroke, are ... treat atrial fibrillation, a common heart rhythm disorder, a new ... also say the drug is especially beneficial for patients with ...
... Aug. 31 (HealthDay News) -- Walk-in retail clinics staffed by ... study has found. , Writing in the Sept. 1 issue ... Dr. Ateev Mehrotra said that retail clinics -- which are ... and other retail chain stores such as Target and Wal-Mart ...
... patients choose where to get their care based on how ... at Fox Chase Cancer Center have recently documented a growing ... at high volume centers, which are generally located in metropolitan ... a study published in the Journal of Clinical Oncology ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Oldest Heart Patients May Get Most From Warfarin 2Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Does the distance a patient has to travel affect where they choose to get their care? 2
... Screen ELISA test system is a qualitative screening ... human sera. When performed according to the directional ... all ANAs commonly tested for, such as those ... SSA, SSB, and Scl-70. The test is also ...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
Medicine Products: